chrisvoncsefalvay/vaers-outcomes huggingface dataset:
sick again; pain in her bones; didn't have milk for 4 weeks/was so dry/every other day, she is able to pump 1 teaspoon of breast milk; fever; This spontaneous case was reported by a consumer and describes the occurrence of BONE PAIN (pain in her bones), ILLNESS (sick again), SUPPRESSED LACTATION (didn't have milk for 4 weeks/was so dry/every other day, she is able to pump 1 teaspoon of breast milk), POOR FEEDING INFANT (her son still doesn't want to touch it or eat any of it) and PYREXIA (fever) in a 42-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. Q36B21A and Q3AA21A) for COVID-19 vaccination.     medical history not provided.  Concurrent medical conditions included Breast feeding.   On 12-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 13-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced BONE PAIN (pain in her bones), ILLNESS (sick again), SUPPRESSED LACTATION (didn't have milk for 4 weeks/was so dry/every other day, she is able to pump 1 teaspoon of breast milk), POOR FEEDING INFANT (her son still doesn't want to touch it or eat any of it) and PYREXIA (fever). At the time of the report, BONE PAIN (pain in her bones), ILLNESS (sick again) and PYREXIA (fever) outcome was unknown, SUPPRESSED LACTATION (didn't have milk for 4 weeks/was so dry/every other day, she is able to pump 1 teaspoon of breast milk) had resolved and POOR FEEDING INFANT (her son still doesn't want to touch it or eat any of it) had not resolved.            Concomitant medications include iron supplements and vitamins for women. No treatment medication information provided. patient  doctor gave her some hormone and did bloodwork which didn't show any issues.   This case was linked to MOD-2021-285020 (Parent-Child Link). This case was linked to MOD-2021-284994 (Patient Link).   See case MOD-2021-285020 for details regarding the child case.
Client report came in 9/8/22, 1 week after administration that injection site (left forearm) is red and painful, with a firm lump present at injection site. Additional a blood vessel had discolored to purple and then red, and the discoloration is reportedly getting longer each day. Client having no systemic symptoms at this time. Client recommended to see provider for assessment.
(R) deltoid deep "achy" and "burning" pain. Dysesthesias in (R) thumb. Muscle tightness (R) upper trapesius. Slight weakness (R) hand (subjective).
site swelling and warm.  whole area of thigh. antibiotic PO BID x 3 D RX and Benadryl Keflex 125 TID x 7 days.
Information has been received from a pharmacist concerning a pt who is "believed to be HIV (+). On an unspecified date, the pt was vaccinated with a 2nd dose of Hep-A virus vaccine inactivated. The reporter stated that, on an unspecified date, antibody titer results "did not show immunity after 2 dose series". The pt sought unspecified medical attention. Additional information has been requested.
Within 1-2 minutes of the administration of 0.1 ml intradermal Jynneos/BN vaccine in left forearm the client stated that he felt lightheaded. He appeared to be diaphoretic. No airway compromise was noted.  No difficulty breathing noted.  Client's legs were elevated onto an adjacent chair and from there was assisted to a supine position on the floor with feet elevated.  No impact injury.  Client was conscious and verbalizing and answering questions appropriately through the entire experience.  Client was given alcohol swab to breathe through nose while vital signs were taken on right upper arm with NIBP device at close intervals.  SaO2 was measured on right index finger.  All VS remained within normal limits.  Privacy screen was placed between clinic traffic and the client.  Client stated (after receiving the vaccine) that he occasionally, but infrequently, feels dizzy when anxious.  When client stated he was feeling improved and diaphoresis had abated, client was transitioned from supine to sitting and then standing positions with vital signs measured at each position change.   Assessment:  vasovagal response secondary to anxiety occasioned by receiving an injection.   Serial right arm vital signs noted below: 2:23 PM - 104/65 supine HR 60  SaO2 98 120/79 supine HR 60  SaO2 99 132/91 sitting HR 58  SaO2 98 177/78 standing HR 66 SaO2 98  When client felt improved and returned to prevaccination state he was transferred to postvaccination waiting area and instructed to remain for an additional 30 minutes before leaving and to communicate with postvaccination area nurses if he felt lightheaded again.
Possible shoulder injury related to vaccine administration (SIRVA) after vaccinations on 9/13/18. Patient complained of shoulder pain bilateral that started 1 week after receiving Tdap booster and seasonal flu vaccine. Sharp right shoulder pain, 5 to 6/10, worsens when lifting arms and moderate left shoulder pain. Patient concerned that vaccines was injected too high on her arm (upper 1/3 deltoid). Patient denies fevers/chills, rashes, flu-like symptoms, polyarthralgia, myalgias. Patient is pregnant, EDD 11/13/18. Meds: prenatal vitamin. No known drug allergy. No other complicated or concerns noted by patient.
This spontaneous report was received from a healthcare worker refers to a 12 months old patient of unknown gender. On 13-OCT-2014, patient was vaccinated with an improperly stored dose of MMR II (lot# J016232, Expiry: 19-DEC-2015, therapy type: HSA, dose number 1) (dose and route was unknown). No adverse effects reported. This is one of the several reports linked with the same reporter link. No further information was available. Additional information has been requested.
HEADACHE; FATIGUE; This spontaneous report received from a consumer concerned a patient of unspecified age and sex. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported. On an unspecified date, the subject experienced headache, and fatigue. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the headache and fatigue was not reported. This report was non-serious.
Following MENACTRA c/o HA, weakness and neck pain, arm soreness. No redness or warmth at injection site.
Started with left ear burning, left arm burning.  Left side of face and behind left eye mild headache.  Burning down left arm/tingling. Hot flash, sweaty, nauseated, rectum felt hot.  Altered taste.  Went to medical clinic and was seen by Dr.
Manled red inflammation @ inj site induration approx 2 1/2" x 3 1/2 - 4" - L arm. Slowly reduced & slight discoloring post 3 wks.
Localized area of cellulitis - R upper arm, fevers, nausea after PNEUMOVAX administration. Pt was treated for other problems (as well as for reaction to PNEUMOVAX) with Clindamycin, Vancomycin.
02/07/22 presents to ED for "Weakness-Generalized". PMHx of "dementia, nonischemic cardiomyopathy, CVA, kidney transplant on cellcept and prograf, liver transplant, UGIB, GERD, PVD, HTN, HLD, DM, chronic back pain, peripheral neuropathy, hepatitis C, anemia, OSA, arthritis, BPH, UTI, right AKA, left transmetatarsal amputation, basal cell carcinoma, squamous cell carcinoma"
muscle  twitching & jerking occurring primarily during sleep;seen by neurologist who dx myoclonus;
No adverse effects.; an 18 month old child was inadvertently administered a partial dose of VAQTA; Information has been received from a nurse referring to a unknown gender 18 month old child. Information about concomitant medications, pertinent medical history and drug reactions/allergies was not reported.  On 09-APR-2019, the patient was inadvertently administered a partial dose of hepatitis a vaccine, inactivated(VAQTA)(lot # R034340, expiration date: 23-NOV-2019, dose, frequency and route were not reported) for prophylaxis (incorrect dose administered). No adverse effects. Information about treatment given for the event, lab diagnostics/studies and medical attention was not provided.
Approximately 3 hrs post vaccine administration pt began c/o leg pain. When seen in clinic next day L thigh (vaccine site) measured 40cm. R thigh 34.5cm. Temp of 100 degrees on Motrin. L thigh red with increased heat. L inguinal node enlarged and tender. Benadryl, IV Clindamycin pain mgmt-Tylenol #3 elevation, Nafcillin, compresses d/c'd on PO Clindamycin.
Vomiting, diarrhea, and rash. The vomiting lasted for 2 days. Diarrhea lasted for 14 days. The rash lasted for 3 1/2 weeks. Took him in to the doctor and was told that he had a reaction to the vaccination and that it was being documented in his list of allergies/sensitivities.
CRYING, HIVES APROX 2 HOURS AFTER RECEIVING VACCINES. SEEN @ ER DX WITH ALLERGIC RXN TO VACCINES TREATED WITH BENADRYL AND PRELONE.
sore arm; tired; irregular thyroid level; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  An adult patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 2, single for covid-19 immunisation. Relevant medical history included: "Heart attack at 31" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE), administration date: Apr2021, for Covid-19 Immunisation, reaction(s): "tired", "Sore arm", "thyroid function abnormal". The following information was reported: PAIN IN EXTREMITY (non-serious), outcome "recovered", described as "sore arm"; FATIGUE (non-serious), outcome "recovered", described as "tired"; THYROID FUNCTION TEST ABNORMAL (non-serious), outcome "recovered", described as "irregular thyroid level". Relevant laboratory tests and procedures are available in the appropriate section.  Additional information: Patient cardiologist approved me using the Pfizer shot, which was done last April. Patient was monitored by a cardiologist, a hematologist, and GP during the weeks after taking it because patient had a previous reaction. No effect on patient heart.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Since the second dose, I have had persistent pain in my right arm in the location of the injections. The pain is a stabbing pain and throbbing. It is not a muscle or joint pain and nothing seems to alleviate this annoyance.; Since the second dose, I have had persistent pain in my right arm in the location of the injections. The pain is a stabbing pain and throbbing. It is not a muscle or joint pain and nothing seems to alleviate this annoyance.; This is a spontaneous report from a contactable consumer, the patient. A 64-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: CR8733) via an unspecified route of administration in the right arm on 05Apr2021 (at the age of 64-years-old) as a single dose for COVID-19 immunisation. Medical history included sinusitis. The patient had no known allergies to medications, food, or other products. The patient did not receive any medications within two weeks of vaccination. The patient previously took the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6207) via an unspecified route of administration in the right arm on an unknown date (age at vaccination unknown) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 05Apr2021 at 18:00, since the second dose, the patient has had persistent pain in her right arm in the location of the injections. The pain was a stabbing pain and throbbing. It was not a muscle or joint pain and nothing seemed to alleviate its annoyance. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events since the second dose, the patient has had persistent pain in her right arm in the location of the injections; the pain was a stabbing pain and throbbing; it was not a muscle or joint pain and nothing seemed to alleviate its annoyance was not resolved at the time of this report.
Pneumonia; Chest pains; Coughing; This serious case was reported by a consumer via interactive digital media and described the occurrence of pneumonia in a patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis.   On an unknown date, the patient received Arexvy. On an unknown date, an unknown time after receiving Arexvy, the patient experienced pneumonia (Verbatim: Pneumonia) (serious criteria GSK medically significant), chest pain (Verbatim: Chest pains) and cough (Verbatim: Coughing). The outcome of the pneumonia, chest pain and cough were not reported.   It was unknown if the reporter considered the pneumonia, chest pain and cough to be related to Arexvy.     It was unknown if the company considered the pneumonia, chest pain and cough to be related to Arexvy.   Additional Information: GSK Receipt Date: 18-Nov-2023 This case was reported by a patient via interactive digital media. The patient reported that he or she received Arexvy vaccine and experienced pneumonia, chest pains and coughing. The patient stated that he or she will ask his or her pulmonologist about this drug. The follow up would not possible as no contact details were available.
pt recv vax 5OCT95 & 18JUN96 pt devel gen lesions described as fluid filled, red, raised bumps;the bumps first appeared on scalp, then spread to face & abd;presented to MD w/resolving chickenpox & ear pain;tx for OM;dx otitis externa;
Information has been received from a 70 year old female patient with sulfa allergy who on 31-JUL-2008 was vaccinated with a single dose of ZOSTAVAX (Merck). Concomitant therapy included TRICOR, metoprolol and PLAVIX. On 19-DEC-2008 the patient experienced shingles around her waist area. The patient mentioned that she experienced a severe pain associated with it. Unspecified blood tests were performed. The patient sought unspecified medical attention. On an unspecified date the patient recovered. Follow-up information has been received from a physician concerning the patient with no history of chickenpox who on 31-JUL-2008 was vaccinated intramuscularly in her left deltoid with a 0.5 mL dose of ZOSTAVAX (Merck) (lot # 659409/0409X). It was reported that the patient had 12 cluster lesions in the right side of her thorax. The patient's maximum temperature was 98.6 degrees. The patient experienced pain at level 8 in a 0-10 scale. She had no recent exposure to chickenpox or shingles. A direct fluorescent antibody was not done. A photo was not taken. The patient recovered. Follow up information was received from a physician who reported that on 31-JUL-2009 a 70 year old female patient was vaccinated with the first dose of ZOSTAVAX (Merck) (lot # 659409/0409X) intramuscularly into her deltoid. It was reported that on 19-DEC-2008 the patient developed herpes zoster clinically diagnosed. The patient recovered on an unspecified date. No further information is available.
Woke up in mmring not feeling well, had a headache, felt warm and dizzy.Had to leave work.Second day, still not feeling good, headach and sorethroat.
Administered vaccines, pt appears to be fine - made her sit for a moment, within 1-2 min after giving vaccine pt states "I do not feel right". She turned pale and sweaty. I laid her back on exam table called for assistance. Her eyes rolled back in head, fists and arms clenched, twitching and body rigid. Episode lasting 45-60 sec. EMS arrived. VS 9:01 - BP 124/79, (R) 52, (P) 92. EMS sat her up on table, another episode happened lasting about 15 sec. EMS concerned she possibly had a seizure. EMS suggested pt go to hospital for further evaluation. D/C at 9:17 to EMS.
Right  side of left hand has gone numb. Experiencing pins and needles in left ring finger and pinky. Small lump has formed on bottom right side of left palm.
Redness, swelling and warmth over arm at and beolw injection site; Rx with Benadryl and ice.
chronic idiopathic urticaria (Hives all over body everyday) with GERD
in the hospital and she has almost died three times since having the vaccine/ITP; This is a spontaneous report from a contactable consumer reported for her granddaughter from a Pfizer sponsored program. A 24-years-old female patient received bnt162b2 (PHIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) at SINGLE dose for covid-19 immunisation  .  The patient medical history was not reported.     The patient's concomitant medications were not reported.  On the next day of vaccination, the patient came down with this condition they called immune thrombocytopenia (ITP), and the patient has been in the hospital and she has almost died three times since having the vaccine. The outcome of the event was unknown.   The lot number for BNT162b2, was not provided and will be requested during follow up.
No patients experienced symptoms; unspecified patients may have been administered improperly stored doses of PEDVAX HIB, GARDASIL 9, RECOMBIVAX HB and ROTATEQ; This spontaneous report was received from a nurse and refers to an unspecified number of patients of unknown age and gender. Information regarding the patient's pertinent medical history, concurrent conditions, concomitant and historical drugs was not provided.  On unknown dates, the patients were vaccinated with improperly stored doses of the following vaccines: Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) (LIQUID PEDVAXHIB) lot # R036178 with expiration date on 09-OCT-2021, and lot # R027329 with expiration date on 12-JUL-2021; HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast) (GARDASIL 9) lot # S026372 and expiration date on 01-APR-2022, and lot # R029507 with expiration date on 10-JUL-2021; Hepatitis B Vaccine (Recombinant) (RECOMBIVAX HB) lot # R031056 with expiration date on 04-JUN-2021, and lot # R031055 with expiration date on 04-JUN-2021; and Rotavirus Vaccine, Live, Oral, Pentavalent (ROTATEQ) orally, lot # 1660685 with expiration date on 21-MAR-2021, and lot # S005875 with expiration date on 30-NOV-2020, (strength, dosing details were not reported) via unknown route, all vaccines for prophylaxis.  It was reported that the vaccines were exposed to a temperature of 47.6-degree Fahrenheit for 41 minutes and 31.9-degree Fahrenheit for 6 hours and 58 minutes. There was not previous temperature excursion. It was reported that digital data logger was involved. No symptoms were reported.  This is a non-valid case due to the lack of patient's identifiers.  Follow-up information was received on 03-MAR-2020 from a nurse supervisor.  The nurse referred to a 4-weeks-old female patient (previously considered non-valid).   On 17-JAN-2020, the patient was vaccinated with improperly stored Hepatitis B Vaccine (Recombinant) (RECOMBIVAX HB) (strength not reported) lot # R031056 with expiration date on 04-JUN-2021 for prophylaxis (product storage error).  The reporter confirmed that there had been no reports of adverse event following the administration of the vaccinations. She also reported that no patients received the Merck vaccination Hemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) (LIQUID PEDVAXHIB). Additional information has been requested.  This is one of the several reports by the same reporter.; Sender's Comments:  US-009507513-2003USA001377: US-009507513-2003USA001374: US-009507513-2003USA001375: US-009507513-2003USA001376: US-009507513-2003USA001378: US-009507513-2001USA006732:
Hot to the touch Injection Site; Hard to the touch Injection Site (After Second Dose); Itching Injection Site (After Second Dose); Swollen Injection Site (After Second Dose); Sore Injection Site (After Second Dose); This spontaneous case was reported by a consumer and describes the occurrence of INJECTION SITE WARMTH (Hot to the touch Injection Site), VACCINATION SITE INDURATION (Hard to the touch Injection Site (After Second Dose)), VACCINATION SITE PRURITUS (Itching Injection Site (After Second Dose)), VACCINATION SITE SWELLING (Swollen Injection Site (After Second Dose)) and VACCINATION SITE PAIN (Sore Injection Site (After Second Dose)) in a 64-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 004C21A and 031B21A) for COVID-19 vaccination.     No Medical History information was reported.   On 14-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 13-May-2021, the patient experienced INJECTION SITE WARMTH (Hot to the touch Injection Site), VACCINATION SITE INDURATION (Hard to the touch Injection Site (After Second Dose)), VACCINATION SITE PRURITUS (Itching Injection Site (After Second Dose)), VACCINATION SITE SWELLING (Swollen Injection Site (After Second Dose)) and VACCINATION SITE PAIN (Sore Injection Site (After Second Dose)). At the time of the report, INJECTION SITE WARMTH (Hot to the touch Injection Site), VACCINATION SITE INDURATION (Hard to the touch Injection Site (After Second Dose)), VACCINATION SITE PRURITUS (Itching Injection Site (After Second Dose)), VACCINATION SITE SWELLING (Swollen Injection Site (After Second Dose)) and VACCINATION SITE PAIN (Sore Injection Site (After Second Dose)) outcome was unknown.            Concomitant product use was not provided by the reporter. No treatment information was provided.   This case was linked to MOD-2021-138827 (Patient Link).
On 2/23/2023, I woke up coughing and with a runny nose and a sore throat. I thought that maybe it was just sinus trouble at first, but the symptoms rapidly worsened. By that evening, the symptoms were much worse; I sometimes was not able to breathe without coughing. Anytime I tried to take a breath, I would get choked up. On 2/23/2023, I took two home antigen tests and got positive results on both of them. About a week after the onset of symptoms, I got to the point where I had chest pains and fatigue that was so severe that I couldn't walk very far without feeling like I would collapse. On 3/3/2023, I went to an urgent care clinic, because my symptoms had not improved. All of the OTC medicines I had taken failed to work. At the urgent care, I was told to go to the ER if my symptoms worsened. The urgent care gave me Tessalon Perles, a Z-Pak, an albuterol inhaler, and amoxicillin. The medicines they prescribed me didn't help at all, so I ended up going to the ER on 3/9/2023. By this point, my cough had gotten worse. At the ER, I was given a breathing treatment and an evaluation. I was prescribed cough syrup, another round of steroids, and more antibiotics. I was pretty much prescribed the same antibiotics as the ones I had been prescribed at the urgent care, only they were much stronger. I tested negative on a home antigen test on 3/12/2023, and I returned to work on 3/13/2023. However, I still had symptoms, such as runny nose and coughing. About a week after returning to work, I experienced partial loss of smell, which lasted for a week. At one point, my coughing and sneezing were so violent that I experienced temporary nerve damage in the lower right side of my back, and this put me out of work for two days. When I returned to work after that, I was not allowed to lift anything above 10 lbs. for two weeks. The coughing, sneezing, and runny nose lasted until about the third week of April 2023. After those symptoms resolved, I felt fine.